
Latest News
Nine Drug Formularies In Canada List Evenity® For Reimbursement For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk Of Fracture
April 3, 2024
Amgen Canada has announced EVENITY’s (romosozumab) inclusion in public formularies, marking a significant step in osteoporosis care for postmenopausal women.
EVENITY has been listed for reimbursement on nine of Canada’s public formularies. With this announcement most postmenopausal women in Canada will be able to access this biologic treatment which received Health Canada approval in 2019.
Click here to visit AMGEN Canada and read the full release.
To learn more about osteoporosis treatments visit https://osteoporosis.ca/treatments/
OC MAKES THE NEWS – RECENT ITEMS
DENOZA® is now available in Canada
Latest News DENOZA® (denosumab injection), a biosimilar from Apotex, is now available in Canada September 25, 2026 PrDENOZA® is indicated for the treatment of postmenopausal osteoporosis, and to increase bone […]
Healthcare Professional Educational Events
Healthcare Professional Educational Events August 19, 2026 View the following information for two events for the healthcare professional: Canadian Symposia on Rare Bone Diseases 2026 ISCD Quality Bone Densitometry: for […]
Researchers Use Machine Learning To Better Predict Fractures Caused By Weak Bones
Latest News Researchers Use Machine Learning To Better Predict Fractures Caused By Weak Bones July 7, 2026 Fragility fractures are a major and growing health burden, with significant personal and […]
